Loading…
Also known as Hydrolysed collagen, Collagen protein
Hydrolysed collagen protein broken into short peptides for absorption; provides glycine and proline as substrate for the body's own collagen synthesis, with trials showing improved skin elasticity and joint comfort after 8-12 weeks.
We link to relevant studies and leave interpretation to you and your healthcare professional.
Number of audited published findings for Collagen Peptides by condition. Drill into a pair page for the full breakdown.
Where people report using it and what trials suggest
Common claims the trials do not support
Hydrolysed collagen with respectable small RCTs for skin elasticity/hydration and OA pain; protein-replacement or muscle-growth claims are wrong.
Safety notes: Well tolerated; choose grass-fed/marine sourcing to avoid contaminants.
Evidence grades reflect study quality and consistency, not marketing claims.
Summaries of published trial results for this compound, grouped by condition. Numbers are reported exactly as the researchers published them — we never calculate or convert.
How to read this table
In short: benefit is what was observed; evidence is how much you should trust the observation. A “Benefit seen” tag on a weak study counts for far less than the same tag on a meta-analysis.
| Outcome measured | What trials found | Effect size | People studied | Duration | Type of evidence | Study |
|---|---|---|---|---|---|---|
| activity-related pain intensity (participant assessment) | Activity-related pain improved by 19.5 vs placebo in 139 people over 12 weeks. (p = 0.046)Benefit seen | 19.5 | 139 | 12 weeks | RCT · 2017 | PMID 28177710 |
| activity-related pain intensity (physician assessment) | Activity-related pain improved by 16.7 vs placebo in 139 people over 12 weeks. (p = 0.021)Benefit seen | 16.7 | 139 | 12 weeks | RCT · 2017 | PMID 28177710 |
| pain intensity under resting conditions |
Associated conditions and community-reported outcomes, wrapped together on one page. Aggregates appear only once enough reports arrive.
How this compound is sold in the UK, and where our readers typically find it.
Retailer search links — we may earn commission on purchases at no cost to you. Commission never affects our evidence ratings.
| No significant benefit for resting pain vs placebo in 139 people over 12 weeks. (p = 0.209)No clear benefit |
| no number reported |
| 139 |
| 12 weeks |
| RCT · 2017 |
| PMID 28177710 |
| range of motion of the knee joint | No significant change in knee range of motion vs placebo in 139 people over 12 weeks.No clear benefit | no number reported | 139 | 12 weeks | RCT · 2017 | PMID 28177710 |
| use of additional therapeutic options | Use of additional treatments significantly reduced vs placebo in 139 people over 12 weeks.Benefit seen | no number reported | 139 | 12 weeks | RCT · 2017 | PMID 28177710 |